• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Intern Med J . Clinical Characteristics and Outcomes of Critically Ill Patients with 1, 2 and 3 doses of Vaccination against COVID-19 in Australia

tetano

Editor, Senior Moderator
Intern Med J


. 2022 Jul 16.
doi: 10.1111/imj.15884. Online ahead of print.
Clinical Characteristics and Outcomes of Critically Ill Patients with 1, 2 and 3 doses of Vaccination against COVID-19 in Australia


Madeleine Otto[SUP] 1 [/SUP], Aidan Jc Burrell[SUP] 1 2 [/SUP], Ary Serpa Neto[SUP] 2 [/SUP], Patricia Villodre Alliegro[SUP] 2 [/SUP], Tony Trapani[SUP] 2 [/SUP], Allen Cheng[SUP] 3 4 [/SUP], Andrew A Udy[SUP] 1 2 [/SUP], SPRINT-SARI Australia Investigators



Collaborators, Affiliations

Abstract

Background: Vaccination has been shown to be highly effective in preventing death and severe disease from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Currently few studies have directly compared vaccinated and unvaccinated patients with severe COVID-19 in the intensive care unit (ICU).
Aims: Our aim was to compare the clinical characteristics and outcomes of vaccine recipients and unvaccinated patients with SARS-CoV-2 infection admitted to the ICU in a nationwide setting.
Materials and methods: Data were extracted from the Short PeRiod IncideNce sTudy of Severe Acute Respiratory Infection Australia, in 57 ICUs during Delta and Omicron predominant periods of the COVID-19 pandemic. The primary outcome was in-hospital mortality. Secondary outcomes included duration of mechanical ventilation, ICU length of stay, hospital length of stay, and ICU mortality.
Results: 2,970 patients were admitted to ICU across participating sites from 26 June 2021 to 8 February 2022. 1,134 (38.2%) patients were vaccine recipients, and 1,836 (61.8%) patients were unvaccinated. Vaccine recipients were older, more comorbid, and less likely to require organ support. Unadjusted in-hospital mortality was greater in the vaccinated cohort. After adjusting for age, gender and comorbid status, no statistically significant association between in-hospital or ICU mortality, and vaccination status, was apparent.
Conclusion: We found COVID-19 infection can cause severe disease and death in vaccine recipients, though comorbid status and older age were significant contributors to mortality. Organ support requirements and the number of deaths were highest in the unvaccinated cohort. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 vaccine; breakthrough infection; intensive care.
 
Back
Top Bottom